AnalystsCaroline PalomequeCaroline Palomeque's Stock Forecasts
AnalystsCaroline Palomeque
Sectors:
Analyst Ranking
Top 31%
#1513 out of 4872 analysts
Average Return
+16.11%
Win Rate
56%5 out of 9
Risk vs Reward
Poor
Good
Caroline Palomeque's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Agile Therapeutics IncAGRX | +146.19% | $1,706.00 | $4,200.00 | 2018-11-28 - 2019-11-29 | Strong Buy |
Krystal Biotech IncKRYS | +51.98% | $121.19 | $184.19 | 2023-09-06 - 2024-09-06 | Strong Buy |
Ascendis Pharma AASND | +16.05% | $86.10 | $99.92 | 2022-08-29 - 2023-08-29 | Strong Buy |
Halozyme Therapeutics IncHALO | +12.27% | $35.70 | $40.08 | 2023-03-26 - 2024-03-26 | Strong Buy |
Denali Therapeutics IncDNLI | +1.56% | $30.19 | $30.66 | 2022-06-22 - 2023-06-22 | Strong Buy |
Caroline Palomeque Analyst Color
Get additional color on Caroline Palomeque's coverage of popular stocks
Caroline Palomeque's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Harmony Biosciences Holdings IncHRMY | 1 | Strong Buy | $59.00 | N/A | Initiates Coverage On | 2 years ago |
Krystal Biotech IncKRYS | 1 | Strong Buy | $154.00 | N/A | Initiates Coverage On | 2 years ago |
Halozyme Therapeutics IncHALO | 1 | Strong Buy | $58.00 | N/A | Reinstates | 2 years ago |
Cerevel Therapeutics Holdings IncCERE | 1 | Hold | $22.00 | N/A | Reinstates | 2 years ago |
Ascendis Pharma AASND | 1 | Strong Buy | $166.00 | N/A | Assumes | 3 years ago |
Denali Therapeutics IncDNLI | 1 | Strong Buy | $39.00 | N/A | Initiates Coverage On | 3 years ago |
Regenxbio IncRGNX | 1 | Strong Buy | $61.00 | N/A | Initiates Coverage On | 3 years ago |
Anavex Life Sciences CorpAVXL | 1 | Strong Buy | $40.00 | N/A | Initiates Coverage On | 3 years ago |
Agile Therapeutics IncAGRX | 1 | Strong Buy | $6,000.00 | N/A | Initiates Coverage On | 6 years ago |
Dare Bioscience IncDARE | 1 | Strong Buy | $36.00 | N/A | Initiates Coverage On | 7 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.